Thirty-two previously unidentified genetic regions associated with osteoporosis and fracture have been identified by a large, worldwide consortium of researchers, including Stanford Prevention Research Center chief John Ioannidis, MD, DSc. Variations in the DNA sequences in these regions confer either risk or protection from the bone-weakening disease. Many, but not all, of the regions encode proteins involved in pathways known to involve bone health. The research shows that osteoporosis results from the combined contributions of dozens, if not hundreds, of genes. It also suggests many new avenues for anti-osteoporosis drug development. "We're learning that the genetic architecture of disease is very complex, " said Ioannidis, who is one of seven senior authors of the study and the methodological leader of the consortium.
The aging baby boomers and subsequent generations will be looking to the food industry to provide products that can help them live longer, healthier and more active lives than previous generations, according to research presented at the Institute of Food Technologists' Wellness 12 meeting. There are 78 million baby boomers, defined by the U.S. Census Bureau as those born from Jan. 1, 1946, to Dec. 31, 1964 in the United States. They began reaching the retirement age of 65 last year, and 10, 000 more will reach that milestone every day for the next 18 years. In addition to seeking products that help them live better lives, they also will be seeking products in the coming years to help with the illnesses and chronic conditions common to older people, such as diabetes, vision loss and bone/joint problems.
Many children with the bone cancer, osteosarcoma, die after the tumor spreads to their lungs. In a critical step toward finding a way to stop metastasis, researchers at Georgetown Lombardi Comprehensive Cancer Center say they have discovered an agent that prevents this type of cancer from spreading to the lungs in mice with the disease. The new agent stops or inhibits "ezrin, " a protein vital to the spread of osteosarcoma, say the researchers who presented their findings today at the American Association for Cancer Research (AACR) Annual Meeting 2012. If proven effective in human studies, their ezrin inhibitor might potentially treat adults whose cancers are fueled by over-expression of this protein, and could be a life-saver for children with bone tumors. "If we can prevent metastatic disease in osteosarcoma, we will significantly improve survival and quality of life for these patients, " says the study's senior investigator, Aykut Ã ren, M.
According to a study in bmj.com, the risk of developing cancer within the first seven years after receiving a metal-on-metal hip replacement is no higher than in the general population, although further long-term studies are required. BBC Newsnight and the BMJ recently investigated potentially high levels of toxic metals from failing hip implants that could affect thousands of people worldwide in the future. The authors also investigated as to why these hip replacements were permitted, regardless of the fact that the risks have been known and documented for decades. The BMJ has a comprehensive range of articles regarding the safety of medical devices that can be viewed here. The investigation was commissioned by the National Joint Registry of England and Wales, which contains over one million procedures from more than 97% of orthopedic units, and executed by researchers from the Universities of Bristol and Exeter, who investigated the validity of these concerns.
Researchers Control Drug Side Effects For Treatment Gains In Phase I Trial Of 2 Targeted Therapies Against Ewing's Sarcoma Tumors
A pair of targeted therapies shrank tumors in some patients with treatment-resistant Ewing's sarcoma or desmoplastic small-round-cell tumors, according to research led by investigators from The University of Texas MD Anderson Cancer Center reported at the AACR Annual Meeting 2012. Five of 17 Ewing's sarcoma patients responded to the combination, with two achieving complete responses, one for 27 weeks. The researchers noted that the ability to manage patients' treatment-related side effects is vital to maintaining the therapy and slowing disease progression. The study was published simultaneously in Clinical Cancer Research, a journal of the American Association for Cancer Research. Ewing's sarcoma primarily affects the bones and occurs most often in teenagers and young adults and relapse is common, said lead researcher Aung Naing, M.